SYRS(Delisted)
Syros·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SYRS
Syros Pharmaceuticals, Inc.
A company that developing gene control medicines for the treatment of cancer and immune-mediated diseases
35 CambridgePark Drive, 4th Floor, Cambridge, Massachusetts 02140
--
Syros Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on November 9, 2011. The company is a biopharmaceutical company dedicated to developing new standards of care for first-line treatment of patients with hematological malignancies. The company is advancing a late-stage clinical program that includes lead product candidates: (i) Tamibarotene, a selective retinoic acid receptor α agonist, and the company is conducting SELECT-MDS-1, a Phase 3 clinical trial evaluating Tamiflu in combination with azacitidine in patients with high-risk myelodysplastic syndromes (HR-MDS). (ii) SY-2101, a new oral form of arsenic trioxide or ATO, which was evaluated in a dose-confirmation study in newly diagnosed patients with low-risk acute promyelocytic leukemia or APL.
Company Financials
EPS
SYRS has released its 2024 Q3 earnings. EPS was reported at -0.16, versus the expected -0.72, beating expectations. The chart below visualizes how SYRS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
